← Eichor
Study identifier: NCT07349654 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Underdilated-stent Technique Improves Post-TIPS Encephalopathy

Condition: Liver Cirrhosis · Variceal Bleeding, Cirrhosis · Ascites Hepatic  ·  Sponsor: The Second Affiliated Hospital of Chongqing Medical University

PhaseNA
Planned participants72
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Transjugular intrahepatic portosystemic shunt (TIPS) is a critical therapeutic approach for managing esophagogastric variceal bleeding and refractory ascites in decompensated cirrhosis patients. To date, hepatic encephalopathy (HE) remains one of the most common complications following TIPS procedures, and prediction and prevention of post-TIPS HE have always been a hotspot in the field of hepatology. However, no reliable clinical studies have confirmed that any drug or intervention can effectively prevent the occurrence of HE episodes following TIPS, including lactulose and rifaximin. Underdilated strategy (UDS) was reported as an development technique proposed in recent years for TIPS procedures, which involves using a small-diameter balloon to dilate the puncture tract and subsequently implanted standard-diameter covered stent (e.g., 8 mm). This allows the stent to maintain a smaller diameter shortly after release, thereby reducing the incidence of hepatic encephalopathy during the postoperative period. Over time, the stent gradually dilates to its normal diameter within months. This period coincides with the higher incidence risk of post-TIPS HE, most commonly occurring within 6 months, especially within the first 3 months after TIPS. Therefore, theoretically, UDS can reduce the occurrence of post-TIPS HE. In terms of clinical research, however, there were still no high quality studies reported the advantages of this technique. Current reported clinical studies were all …

This description comes directly from the study's public registry record.

Talk to the study team

Yongjun Zhu, Doctor  ·  86-13281121937  ·  hp545204493@126.com

Always discuss trial participation with your own doctor first.

Locations (2)

The Second Affiliated Hospital of Chongqing Medical UniversityChongqing, Chongqing Municipality, ChinaRecruiting
Qianjiang Central HospitalQianjiang, Chongqing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07349654